Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer

Inclusion Criteria: * The patient has given informed consent. * The patient is willing and able to abide by the protocol. * The patient is between age 18 and 70 (between 19 and 70 in Alabama). * The patient has histologically proven NSCLC with radiologically documented brain metastases. * Newly diagnosed or stable systemic disease, on or off systemic therapy. * If receiving systemic therapy for NSCLC, at least two weeks since patient received systemic therapy. * Able to withhold systemic therapy for duration of WBRT therapy. * If the patient is of childbearing potential, he/she is using an acceptable/effective method of contraception. * The patient's Karnofsky Score is greater than or equal to 70%. Exclusion Criteria: * Patient has a diagnosis of recurrent brain metastases. * The patient has an absolute neutrophil count less than or equal to 1.5 X 10 9/L. * The patient has a screening platelet count less than 100,000/uL. * The patient has a screening bilirubin greater than 1.6 mg/dL. * The patient has a screening creatinine greater than 2.25 mg/dL in men and 1.8 mg/dL in women. * The patient has a screening ALT/AST greater than 2.5 times the upper limit of the laboratory reference range. * The patient has an unstable medical condition or significant comorbid pathophysiology (e.g. active infection, poorly controlled diabetes, unstable angina, severe heart failure) that would interfere with his/her participation in the study. * The patient is enrolled, or plans to enroll, in a concurrent treatment protocol with another investigational product. * The patient has received prior chemotherapy or radiation therapy within two weeks of beginning WBRT on protocol. * The patient is allergic to gadolinium contrast. * More than 21 days has or will elapse between the brain MRI documenting the brain metastases and the initiation of WBRT.